Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8434830 | Cancer Letters | 2018 | 9 Pages |
Abstract
This study provides evidence that systemically administered anti-PD-1 treatment is unlikely to exacerbate pre-existing T cell-mediated inflammation outside the tumor in obesity-associated cancers, such as EAC. Furthermore, our data suggests that studies are required to identify the negative impact of concomitant therapies on PD-1 expression in order to boost overall response rates.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Karen C. Galvin, Melissa J. Conroy, Suzanne L. Doyle, Margaret R. Dunne, Ronan Fahey, Emma Foley, Katie E. O'Sullivan, Derek G. Doherty, Justin G. Geoghegan, Narayanasamy Ravi, Cliona O'Farrelly, John V. Reynolds, Joanne Lysaght,